Inhibitor Therapeutics, Inc.

What they do

The company develops therapies based on already approved active pharmaceuticals with patent-protected methods of use or delivery. Its primary program targets BCCNS cancers using itraconazole, an FDA-approved antifungal. It holds an exclusive worldwide license from Johns Hopkins University to a patent covering prostate cancer, basal cell carcinoma, and lung cancer treatments. The company has engaged Avior Bio to develop a novel itraconazole formulation and Frameshift Management for regulatory consulting.

Revenue drivers

• No commercial products — The company has no approved products and has generated no revenue to date.
• Potential royalties from JHU license — Mid-single digit royalties on net sales of licensed products, with higher rates for US exclusivity, plus sublicensing income.
• Milestone payments from JHU license — Up to $3.0 million in development milestones tied to Phase 3 trial success, commercialization, and FDA approval.

Recent performance

In 2025, the company reported a net loss of $3.3 million, consistent with 2024, and negative operating cash flow of $3.2 million. As of March 31, 2026, total assets were $1.4 million, with cash and equivalents of $1.3 million. Shareholder equity was negative at $2.0 million, and total liabilities were $3.4 million. The company has been pre-revenue since inception.

Strategy

Management is focused on advancing the lead BCCNS program by obtaining FDA feedback on a 505(b)(2) development pathway. They submitted a regulatory meeting request and briefing materials to the FDA in February 2026, with Frameshift's support. The company is also evaluating opportunities to acquire or license additional pre-clinical and clinical stage therapeutics, particularly those repurposing existing approved drugs. A website overhaul reflects the ongoing direction to develop its intellectual property and acquire additional assets.

Risks

• FDA pathway uncertainty — The FDA may disagree with the proposed endpoint framework, require additional data, or determine the existing HP2001 dataset is insufficient for filing.
• Intellectual property risk — Patent applications may not issue, may have narrower claims, or may be challenged, and orphan-drug exclusivity is not guaranteed.
• Capital needs — The company may need additional capital or strategic transactions to fund development, and such funding may not be available on acceptable terms.
• Minimal operations — The company presently conducts only minimal operations, which increases dependence on outsourced partners and limited internal resources.

Outlook

Management expects to continue preparing for a pre-IND and NDA for the novel itraconazole formulation, subject to FDA feedback from the granted Type C meeting. Avior has completed formulation development and will conduct a PK crossover study. The company also anticipates making remaining minimum annual royalty payments of $50,000 to JHU starting January 1, 2027, until the first commercial sale.